ADMA
ADMA
US0008991046
ADMA Biologics Inc
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 100/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±59.1% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).

Beta (Market Relation)
0.69x
Defensive
Volatility (5Y p.a.)
59.1% p.a.
5-Year Horizon
Max Drawdown (5Y)
-69.0%
5-Year Horizon
Sharpe Ratio
0.90
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -29.3%
3 Years 57.3% -69.0% 0.75 +45.7%
5 Years 59.1% -69.0% 0.9 +55.9%
10 Years 68.4% -84.1% 0.03 +4.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (59.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -84.1% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
6 ISS Score: 6 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
5 ISS Score: 5 / 10
Short Ratio
12.18
ende